Hypotension duration and vasopressor requirements following intrathecal oxytocin for Total hip arthroplasty: Secondary analysis of a randomized controlled trial.

Henshaw DS, Khanna AK, Edwards CJ, Eisenach JC

Journal of clinical anesthesia23 Jun 2023Cited by 3 (Europe PMC)

PMID37356196PMCIDPMC10350898DOI10.1016/j.jclinane.2023.111189PepBankPUB-37356196

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialSafety outcome
In patients having total hip arthroplasty, intrathecal oxytocin did not change the duration of hypotension in the first 60 minutes compared with placebo.
In plain wordsIn people having hip replacement, oxytocin given in the spine did not change how long blood pressure stayed low, compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeDuration of hypotension in the first 60 min after spinal placement
Study
n = 90
Comparator
Placebo (saline)
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Studied dose
100 μg · intrathecalAs given in this study (human).
Measurements
Hypotension duration
12.2 min
intrathecal oxytocin
Hypotension duration
14 min
placebo
Source sentences
Summary
The duration of hypotension during the first 60 min following spinal placement did not differ between intrathecal oxytocin and placebo groups (12.2 ± 10.7 vs 14.0 ± 13.0 min, respectively; p = 0.476).
2 context sentences(design, population, supporting numbers)
Summary · context
90 patients were included in the analysis (44 randomized to spinal oxytocin and 46 to placebo [saline]).
Summary · context
Compared to saline control, intrathecal oxytocin, 100 μg did not increase the duration of hypotension or vasopressor requirements in patients during total hip arthroplasty.
Report a problemFND-3735619601
02HumanRandomized controlled trialSafety outcome
In patients having total hip arthroplasty, intrathecal oxytocin did not change cumulative vasopressor requirements in the first 60 minutes compared with placebo.
In plain wordsIn people having hip replacement, oxytocin given in the spine did not change the amount of blood pressure medicine needed, compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeCumulative vasopressor requirement in the first 60 min
Study
n = 90
Comparator
Placebo (saline)
Analysis
Primary
Outcome group
Blood pressure · Cardiovascular
Studied dose
100 μg · intrathecalAs given in this study (human).
Measurements
Cumulative vasopressor requirement
1303 μg (phenylephrine equivalents)
intrathecal oxytocin
Cumulative vasopressor requirement
1156 μg (phenylephrine equivalents)
placebo
Source sentences
Summary
There was also no difference in cumulative vasopressor requirements (1303 ± 883 vs 1156 ± 818 μg [phenylephrine equivalents]; p = 0.413) during that time period.
2 context sentences(design, population, supporting numbers)
Summary · context
90 patients were included in the analysis (44 randomized to spinal oxytocin and 46 to placebo [saline]).
Summary · context
Compared to saline control, intrathecal oxytocin, 100 μg did not increase the duration of hypotension or vasopressor requirements in patients during total hip arthroplasty.
Report a problemFND-3735619602
03HumanRandomized controlled trialSafety outcome
In patients having total hip arthroplasty, intrathecal oxytocin showed no group differences from placebo for any investigated secondary outcome.
In plain wordsIn people having hip replacement, oxytocin given in the spine showed no differences from placebo in the other outcomes measured.
Peptide
Oxytocin
Outcome
No significant changeOther secondary outcomes (later hypotension and vasopressor time points, fluids)
Study
n = 90
Comparator
Placebo (saline)
Analysis
Secondary
Outcome group
Blood pressure · Cardiovascular
Studied dose
100 μg · intrathecalAs given in this study (human).
Source sentences
Summary
No group differences were found for any of the investigated secondary outcomes.
2 context sentences(design, population, supporting numbers)
Summary · context
90 patients were included in the analysis (44 randomized to spinal oxytocin and 46 to placebo [saline]).
Summary · context
Compared to saline control, intrathecal oxytocin, 100 μg did not increase the duration of hypotension or vasopressor requirements in patients during total hip arthroplasty.
Report a problemFND-3735619603
04HumanRandomized controlled trialEfficacy outcome
In patients having total hip arthroplasty, physical therapy metrics did not differ between intrathecal oxytocin and placebo.
In plain wordsIn people having hip replacement, oxytocin given in the spine did not change physical therapy results, compared with placebo.
Peptide
Oxytocin
Outcome
No significant changePhysical therapy related metrics
Study
n = 90
Comparator
Placebo (saline)
Analysis
Secondary
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
100 μg · intrathecalAs given in this study (human).
Source sentences
Summary
The oxytocin and placebo groups also did not differ in regards to physical therapy related metrics, time to first opioid administration, cumulative opioids at 24-h, or pain scores through 24-h.
2 context sentences(design, population, supporting numbers)
Summary · context
90 patients were included in the analysis (44 randomized to spinal oxytocin and 46 to placebo [saline]).
Summary · context
Compared to saline control, intrathecal oxytocin, 100 μg did not increase the duration of hypotension or vasopressor requirements in patients during total hip arthroplasty.
Report a problemFND-3735619604
05HumanRandomized controlled trialEfficacy outcome
In patients having total hip arthroplasty, time to first opioid did not differ between intrathecal oxytocin and placebo.
In plain wordsIn people having hip replacement, oxytocin given in the spine did not change the time to first opioid, compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeTime to first opioid administration
Study
n = 90
Comparator
Placebo (saline)
Analysis
Secondary
Outcome group
Pain · Nervous system and cognition
Studied dose
100 μg · intrathecalAs given in this study (human).
Source sentences
Summary
The oxytocin and placebo groups also did not differ in regards to physical therapy related metrics, time to first opioid administration, cumulative opioids at 24-h, or pain scores through 24-h.
2 context sentences(design, population, supporting numbers)
Summary · context
90 patients were included in the analysis (44 randomized to spinal oxytocin and 46 to placebo [saline]).
Summary · context
Compared to saline control, intrathecal oxytocin, 100 μg did not increase the duration of hypotension or vasopressor requirements in patients during total hip arthroplasty.
Report a problemFND-3735619605
06HumanRandomized controlled trialEfficacy outcome
In patients having total hip arthroplasty, cumulative opioid use at 24 hours did not differ between intrathecal oxytocin and placebo.
In plain wordsIn people having hip replacement, oxytocin given in the spine did not change total opioid use over 24 hours, compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeCumulative opioid consumption at 24 h
Study
n = 90
Comparator
Placebo (saline)
Analysis
Secondary
Outcome group
Pain · Nervous system and cognition
Studied dose
100 μg · intrathecalAs given in this study (human).
Source sentences
Summary
The oxytocin and placebo groups also did not differ in regards to physical therapy related metrics, time to first opioid administration, cumulative opioids at 24-h, or pain scores through 24-h.
2 context sentences(design, population, supporting numbers)
Summary · context
90 patients were included in the analysis (44 randomized to spinal oxytocin and 46 to placebo [saline]).
Summary · context
Compared to saline control, intrathecal oxytocin, 100 μg did not increase the duration of hypotension or vasopressor requirements in patients during total hip arthroplasty.
Report a problemFND-3735619606
07HumanRandomized controlled trialEfficacy outcome
In patients having total hip arthroplasty, pain scores through 24 hours did not differ between intrathecal oxytocin and placebo.
In plain wordsIn people having hip replacement, oxytocin given in the spine did not change pain scores over 24 hours, compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeVerbal pain scores through 24 h
Study
n = 90
Comparator
Placebo (saline)
Analysis
Secondary
Outcome group
Pain · Nervous system and cognition
Studied dose
100 μg · intrathecalAs given in this study (human).
Source sentences
Summary
The oxytocin and placebo groups also did not differ in regards to physical therapy related metrics, time to first opioid administration, cumulative opioids at 24-h, or pain scores through 24-h.
2 context sentences(design, population, supporting numbers)
Summary · context
90 patients were included in the analysis (44 randomized to spinal oxytocin and 46 to placebo [saline]).
Summary · context
Compared to saline control, intrathecal oxytocin, 100 μg did not increase the duration of hypotension or vasopressor requirements in patients during total hip arthroplasty.
Report a problemFND-3735619607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 02:48 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.